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Although inflammation in the brain is meant as a
defense mechanism against neurotoxic stimuli,
increasing evidence suggests that uncontrolled,
chronic, and persistent inflammation contributes
to neurodegeneration. Most neurodegenerative
diseases have now been associated with chronic
inflammation, including Alzheimer’s disease (AD).
Whether anti-inflammatory approaches can be
used to treat AD, however, is a major unanswered
question. We recently demonstrated that monoacyl-
glycerol lipase (MAGL) hydrolyzes endocannabi-
noids to generate the primary arachidonic acid pool
for neuroinflammatory prostaglandins. In this study,
we show that genetic inactivation of MAGL attenu-
ates neuroinflammation and lowers amyloid b levels
and plaques in an AD mouse model. We also find
that pharmacological blockade of MAGL recapitu-
lates the cytokine-lowering effects through reduced
prostaglandin production, rather than enhanced en-
docannabinoid signaling. Our findings thus reveal
a role of MAGL in modulating neuroinflammation
and amyloidosis in AD etiology and put forth MAGL
inhibitors as a potential next-generation strategy for
combating AD.INTRODUCTION
Neuroinflammation is a fundamental underlying hallmark of Alz-
heimer’s disease (AD), a debilitating neurodegenerative condi-
tion marked by accumulation of extracellular amyloid plaques
and intracellular neurofibrillary tangles composed of aggregated
amyloid b (Ab) and hyperphosphorylated tau, respectively,
leading to progressive cognitive impairment and dementia
(Glass et al., 2010). Suppressing inflammation has been shown
to reduce AD pathological hallmarks as well as cognitive and
behavioral deficits in AD models (Choi and Bosetti, 2009; Liu
et al., 2012). Recently, there has been considerable interest inexploring the therapeutic potential of anti-inflammatory agents
to prevent, treat, or slow the progression of AD (Aı¨d and Bosetti,
2011; Cunningham and Skelly, 2011).
Ablation of cyclooxygenases (COX) 1 or 2 with nonsteroidal
anti-inflammatory drugs (NSAIDs) or in COX1 or COX2 knockout
mice reduces prostaglandins and suppresses neuroinflamma-
tion, concordant with significant improvements in cognitive,
behavioral, and memory impairments as well as reductions in
Ab plaques and hyperphosphorylated tau in AD mouse models
(Choi and Bosetti, 2009; Kotilinek et al., 2008; McKee et al.,
2008). Retrospective human epidemiological studies have also
demonstrated protective effects or delayed onset of AD upon
prolonged NSAID treatment when initiated early or before
disease initiation, respectively (Rogers et al., 1993; Szekely
et al., 2008); however, NSAIDs have not shown efficacy in AD
patients with mild to moderate cognitive impairment (Imbimbo
et al., 2010). Other anti-inflammatory strategies have also shown
efficacy at reducing pathology in animal models, including treat-
ment with antitumor necrosis factor-a (TNF-a) or interleukin-1b
(IL-1b) antibodies (Kitazawa et al., 2011; Shi et al., 2011). Phar-
macological intervention based on chronic treatment with COX
inhibitors or treatment with anticytokine therapies, however, is
not ideal for long-term use due to their respective gastrointes-
tinal (COX1-selective), cardiovascular (COX2-selective), or im-
munosuppressive (anticytokine therapies) side effects (Ng and
Chan, 2010; Raychaudhuri et al., 2009). Novel and safer anti-
inflammatory strategies are thus required not only to gain a
deeper understanding of the role that inflammation plays in AD
disease progression, but also to investigate its therapeutic
potential in combating AD.
We have recently discovered that monoacylglycerol lipase
(MAGL), an enzyme that terminates the signaling of the anti-
inflammatory endocannabinoid signaling lipid 2-arachidonoylgl-
cerol (2-AG) (Long et al., 2009), also controls arachidonic acid
(AA) release for the production of proinflammatory eicosanoids
(which include lipids such as prostaglandins and thromboxanes)
in the brain (Nomura et al., 2011). We found that genetic and
pharmacological blockade of MAGL not only leads to enhanced
endocannabinoid levels, but also reduced prostaglandins in the
brain under both basal and inflammatory states.
In this study, we asked whether MAGL inactivation modulates
AD pathogenesis in amousemodel of Ab deposition. We presentCell Reports 1, 617–623, June 28, 2012 ª2012 The Authors 617
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Figure 1. A Dysregulated Endocannabinoid-Eicos-
anoid Network in a Mouse Model of Alzheimer’s
Disease
(A) Comparative metabolomic profiling of PS1/APP+
compared to PS1/APP mouse brain lipidomes mea-
suring levels of endocannabinoids; 2-AG (C20:4 mono-
acylglycerol (MAG)), anandamide (C20:4 N-acylethanol-
amines (NAEs)), arachidonic acid (C20:4 free fatty acids
[FFAs]), and eicosanoids (prostaglandin E2 (PGE2), PGD2,
and thromboxane B2 [TXB2]). Elevations in other MAGs,
NAEs, and FFAs, as well as phosphatidic acids (PAs),
lysophosphatidyl cholines (LPCs), and cholesteryl esters
are also depicted. LPCs, MAGs, and NAEs mass/charge
ratios (m/z) are represented as [M+H]. PAs, eicosanoids,
and FFAs are represented as [M-H]. Cholesteryl esters are
represented as loss of fatty acid and [M+H-H2O]+. Data
were obtained from untargeted and multiple reaction
monitoring (MRM)-based targeted LC/MS analysis. The
data shown in Figure 1A represent metabolites that are
significantly altered (p < 0.05) by greater than 1.5-fold in
the PS1/APP+ compared to PS1/APP mouse brain
(n = 4–5 mice/group) by two-tailed t test (raw data in Table
S1). The y axis denotes mass over charge ratio (m/z), the
x axis represents retention time on liquid chromatography,
and the size of the circles represent relative fold-change
of the metabolite between PS1/APP+ compared to wild-
type PS1/APP mouse brain lipidomes. There were no
metabolites that were reduced >1.5-fold in PS1/APP+
brains. Data represent only the metabolites that were
consistently altered in two separate experiments each
including n = 4–5 mice/group.
(B) MAGL hydrolyzes the endocannabinoid 2-AG to
release the dominant source of AA for COX-mediated
eicosanoid (e.g., PGE2, PGD2, TXB2) production in
the brain. TXB2 is a nonbioactive breakdown product of
TXA2.
(C) Brain endocannabinoid and eicosanoid levels deter-
mined by multiple reaction monitoring (MRM) using a
QQQ-LC/MS fromMgll+/+/PS1/APP,Mgll//PS1/APP,
Mgll+/+/PS1/APP+, Mgll//PS1/APP+ mouse brains.
Data are means ± SEM, n = 4–8 mice/group for (A)
and n = 7–8 mice/group for (C). Significance is shown
as *p < 0.05, **p < 0.01 using a linear model with ANOVA.direct evidence thatMAGL inactivation reduces proinflammatory
prostaglandins and cytokine signaling machinery, and produces
profound suppression of neuroinflammation and reductions in
Ab levels and plaque burden.618 Cell Reports 1, 617–623, June 28, 2012 ª2012 The AuthorsRESULTS
Metabolomic Profiling of PS1/APP+
AD Mouse Model
To identify dysregulatedmetabolic networks that
underlie AD pathophysiology, we profiled the
lipidome of the PS1/APP+ mouse brains, which
exhibit an age dependent elevation in Ab levels
and plaque deposition (Figure S1). Using a
combination of targeted and untargeted liquid
chromatography/mass spectrometry (LC/MS)-
basedmetabolomic profiling platforms,we iden-
tified several classes of lipids that were elevated
in thePS1/APP+mousebrains compared to theirwild-type counterparts (Figure 1A), including monoacylglycerols
(MAGs), N-acylethanolamines (NAEs), free fatty acids (FFAs),
eicosanoids, phosphatidic acids (PAs), lysophosphatidyl
cholines (LPCs), and cholesteryl esters. Among this metabolic
signature, we were particularly intrigued by the heightened
endocannabinoid and eicosanoid levels in PS1/APP+ brains
(Figure 1A; Table S1).We postulated that the elevated eicosanoid
levels inPS1/APP+mousebrainsweredrivenbyMAGL-mediated
2-AG hydrolysis and AA release (Figure 1B).
Genetic Ablation of MAGL Reduces Neuroinflammatory
Eicosanoid Levels in the PS1/APP+ AD Mouse Model
To determine whether MAGL contributes to eicosanoid produc-
tion, neuroinflammation, and pathophysiology in the PS1/APP+
mouse brain, we bred MAGL-disrupted (Mgll/) (Chanda
et al., 2010) and PS1/APP+ transgenic mice (Samaroo et al.,
2012) to generate four genotypes for our studies: Mgll+/+/PS1/
APP, Mgll+/+/PS1/APP+, Mgll//PS1/APP, and Mgll//
PS1/APP+. We found that Mgll//PS1/APP and Mgll//PS1/
APP+ mice presented higher levels of the MAGL substrate
2-AG (C20:4 MAG) and dramatically reduced levels of AA
(C20:4 FFA), prostaglandins (PGE2 and PGD2), and throm-
boxane B2 (TXB2) in their brains compared to their Mgll+/+/
PS1/APP and Mgll+/+/ PS1/APP+ counterparts, respectively
(Figure 1C; Table S1). In contrast, the second major endocanna-
binoid, anandamide (C20:4 NAE), although elevated in PS1/
APP+ mouse brains, was not altered upon genetic deficiency
of MAGL (Figure 1C; Table S1). These results show that PS1/
APP+ mice have heightened levels of proinflammatory prosta-
glandins that are generated primarily by MAGL-mediated hydro-
lysis of 2-AG, and that blocking this enzyme can restore prosta-
glandins to basal or subbasal levels.
MAGL Inactivation Attenuates Neuroinflammation
and Ab Levels and Plaque Burden in the PS1/APP+
Mouse Brain
We next addressed whether genetic ablation of MAGL reduces
neuroinflammation in PS1/APP+ mice. We found that PS1/
APP+ mice exhibit significant astrocyte and microglial activation
concordant with elevations in proinflammatory cytokines and
cytokine receptors (Figures 2A–2C). Intriguingly, this observed
microglial and astrocyte activation was almost completely atten-
uated in the Mgll//PS1/APP+ mouse brains assessed both
by GFAP and Iba-1 immunohistochemical staining and quantita-
tive RT-PCR of GFAP and CD11b, respectively (Figures 2A and
2B). Consistent with an antiinflammatory effect of MAGL inacti-
vation, we also observed dramatic reductions in the inflamma-
tory cytokines IL-1b, IL-6, TNF-a, and TNF-a receptor II (TNFRII)
at the mRNA or active protein level (Figure 2C). We next as-
sessed whether disruption of MAGL and reduction of neuroin-
flammation impacts Ab levels and deposition in the transgenic
mouse brain. We found that MAGL inactivation drastically
reduced numbers of Ab plaques (Figure 3A) and brain levels of
total Ab, as well as the Ab40, and Ab42 amyloidogenic peptides
(Figure 3B). Quantitative RT-PCR, conducted to ensure that
inactivation of MAGL did not lead to alteration in the transgene
expression, revealed no detectible changes in human APP
gene expression in the Mgll//PS1/APP+ mice compared to
the PS1/APP+ mice (Figure S2). Collectively, our results show
that MAGL inactivation suppresses neuroinflammation in the
PS1/APP+ AD mouse model, leading to a substantial reduction
in amyloid plaque burden.Pharmacological Blockade of MAGL in the PS1/APP+
AD Model
We next asked whether pharmacological inactivation of MAGL
in PS1/APP+mice, with treatment initiated at 6 months well after
the onset of elevated Ab levels (Figure S1) and formation of
amyloid plaques, recapitulates themetabolic and anti-inflamma-
tory effects observedwith genetic deficiency ofMAGL.We found
that subchronic MAGL blockade with the selective inhibitor
JZL184 (40 mg/kg intraperitoneally [i.p.], once per day over
16 days) in PS1/APP+ mice, produced elevations in 2-AG and
substantial reductions in AA, proinflammatory prostaglandins,
and thromboxanes (Figure 4A).We found that JZL184 also signif-
icantly reduced proinflammatory cytokine levels in PS1/APP+
mouse brains (Figures 4B and 4C). To investigate whether these
eicosanoid and cytokine-lowering anti-inflammatory effects of
the MAGL inhibitors were due to enhancements in 2-AG
signaling versus an attenuation of eicosanoid production, we
included a treatment arm in which JZL184 was coadministered
with cannabinoid receptor type 1 and 2 (CB1 and CB2) antago-
nists, rimonabant and AM630 (3 mg/kg i.p.), respectively. We
found that the reductions in both proinflammatory prostaglan-
dins and cytokines were not reversed upon treatment with
cannabinoid receptor antagonists (Figure 4B), suggesting that
the anti-inflammatory effects observed are mediated primarily
by reductions in AA levels and prostaglandin signaling, rather
than heightened endocannabinoid action.
DISCUSSION
One of the common hallmarks of neurodegenerative diseases,
including AD, is chronic and persistent neuroinflammation,
which in most cases is involved in exacerbating neuronal loss
and disease pathology (Glass et al., 2010). Anti-inflammatory
strategies have thus been proposed as an attractive approach
toward combating AD (Glass et al., 2010). In this study, we reveal
a heretofore unrecognized neuroprotective role of MAGL inacti-
vation as a strategy for quelling neuroinflammation and amyloi-
dogenesis that subserves AD.
Several reports have shown that select patterns of microglial
activation can lead to phagocytosis and clearance of Ab plaques
in mouse models of AD (Jantzen et al., 2002; Lemere and Mas-
liah, 2010; Stahl et al., 2006). In contrast, our results show that
reducing neuroinflammation in the PS1/APP+ transgenic AD
mouse model leads to a dramatic decrease in brain amyloid pla-
ques. Our results are supported by multiple studies showing that
inactivation of the cyclooxygenases or directly blocking cytokine
action with antibodies improves memory function and reduces
neuroinflammation and amyloid plaques in mouse AD models
(Choi and Bosetti, 2009; Kitazawa et al., 2011; McKee et al.,
2008; Shi et al., 2011).
Despite considerable evidence associating neuroinflamma-
tion to AD pathophysiology (Glass et al., 2010), the precise
mechanisms by which it affects Ab plaques or AD disease
progression are not as well understood. One possible mecha-
nism is the inflammatory regulation of b-secretase (BACE1),
the protease that cleaves APP to form Ab, which possesses an
NFkB site in its promoter and is upregulated upon inflammatory
stimuli (Chen et al., 2011; Sastre et al., 2008). Anti-inflammatoryCell Reports 1, 617–623, June 28, 2012 ª2012 The Authors 619
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Figure 2. MAGL Inactivation Attenuates Gliosis and Neuroinflammation in PS1/APP+ Mouse Brains
(A and B) Immunohistochemical analysis of astrocytes (A) and microglia (B) in Mgll+/+/PS1/APP, Mgll+/+/PS1/APP+, and Mgll//PS1/APP+ mouse brains
determined by GFAP (A) and Iba-1 staining (B), respectively, and by quantitative RT-PCR for GFAP (A) or CD11b (B) mRNA expression in cortical brain.
Representative images of n = 4–5 mice/group are shown. Scale bars for images are 20 mm.
(C) Measurements of proinflammatory cytokines and receptors in Mgll//PS1/APP, Mgll+/+/PS1/APP, Mgll+/+/PS1/APP+, and Mgll//PS1/APP+ mouse
brains determined by quantitative RT-PCR of IL-1b, TNF-a, and TNFRII gene expression from hippocampus or cortex and ELISA-based protein quantitation for
IL-1b, IL-6, and TNF-a from soluble proteomes of whole mouse brain. Data are means ± SEM, n = 4–5 mice/group. Significance is shown as *p < 0.05, **p < 0.01
using ANOVA with Tukey-Kramer post-hoc test.agents such as NSAIDs and peroxisome proliferator-activated
receptor-g (PPAR-g) agonists have been shown to reduce the
expression and activity of b-secretase and lower Ab secretion
(Sastre et al., 2003).620 Cell Reports 1, 617–623, June 28, 2012 ª2012 The AuthorsEarlier studies have implicated phospholipases, such as
cPLA2, as the primary driver for AA release for prostaglandin
synthesis (Bonventre et al., 1997). We recently discovered
that, although cPLA2 does contribute to a significant portion
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Figure 3. MAGL Ablation Reduces Amyloid
Plaques in PS1/APP+ Mouse Brain
(A) Quantification of amyloid plaques inMgll+/+/PS1/APP,
Mgll+/+/PS1/APP+, and Mgll//PS1/APP+ mouse brains
determined by thioflavin S staining (Ctx: Cortex; Hipp:
Hippocampus). Quantitation of the number of amyloid
plaques per section per mouse is shown. Thioflavin S
images on the left panel are representative. Scale bars for
images represent 400 and 100 mm, respectively, for the
left and right panels.
(B) Quantitation of total Ab, Ab40, and Ab42 protein levels by
DELFIA. Data are means ± SEM, n = 4–5 mice/group.
Significance is shown as *p < 0.05, **p < 0.01 using ANOVA
with Tukey-Kramer post-hoc test for (A) and two-tailed
t test for (B).
See also Figures S1 and S2.of proinflammatory prostaglandins, MAGL contributes the
majority of AA for eicosanoid synthesis in the brain both
basally and under the lipopolysaccharide-paradigm of neuro-
inflammation (Nomura et al., 2011). Moreover, genetic deletion
of diacylglycerol lipase (DAGL), the enzyme that synthesizes
2-AG, leads to reduction in brain AA levels (Gao et al., 2010),
further supporting a role for endocannabinoid metabolism
as a source for brain AA. Nevertheless, genetic and pharmaco-
logical ablation of cPLA2 has also been shown to ameliorate
cognitive deficits and reduce brain eicosanoid levels in
APP transgenic mice (Sanchez-Mejia et al., 2008). These
results collectively suggest that both MAGL and cPLA2 may
contribute to the generation of AA for prostaglandin production
in AD.
We show here that pharmacological blockade of MAGL
over a 16 day dosing regimen raises endocannabinoid levels
and lowers prostaglandin production, recapitulating the eicosa-
noid and cytokine-lowering effects observed with genetic dele-
tion of MAGL. We found, however, that cannabinoid receptor
signaling is likely not involved in lowering MAGL-driven neuro-
inflammation in PS1/APP+ mice, despite previous studies
showing neuroprotective benefits derived from both enhancing
cannabinoid effects or lowering eicosanoid levels in AD
(Aı¨d and Bosetti, 2011; Bisogno and Di Marzo, 2010; Martı´n-
Moreno et al., 2012). The lack of cannabinoid-mediated effects
in our study may be due to functional desensitization of the
cannabinoid system that results from chronic and complete
MAGL blockade (Schlosburg et al., 2010). It would therefore
be of future interest to test whether partial MAGL blockade
can elicit additive or synergistic benefits against AD by maintain-
ing CB1 signaling and suppressing prostaglandin pathways
simultaneously.Cell Reports 1Despite their well-documented protective
effects when initiated early and taken over pro-
longed periods (Rogers et al., 1993; Vlad et al.,
2008), an issue with NSAIDs has been their
lack of efficacy in AD clinical studies (Imbimbo
et al., 2010; McGeer and McGeer, 2007). We
believe that anti-inflammatory agents may be
most beneficial when treatment is initiated
during amyloidogenesis but before neuronalloss and synaptic failure, since anti-inflammatory agents will
not likely reverse neurodegeneration.
Beyond its anti-inflammatory roles, enhancing endocannabi-
noid signaling has also been shown to promote neurogenesis
and improve memory (Aguado et al., 2005; Galve-Roperh
et al., 2007; Pan et al., 2011). In this study, we have not yet
formally demonstrated the efficacy of MAGL inhibitors at
lowering amyloid plaques or improving memory or behavior. It
will thus be of future interest to test whether MAGL inhibitors
provide therapeutic efficacy toward these parameters.
Our metabolomic profiling showed altered endocannabinoid
and eicosanoid brain metabolism in the PS1/APP+ AD mouse
model, alongside alterations in certain phospholipids and cho-
lesteryl esters. Our findings are consistent with previous studies
showing that lowering eicosanoids or cholesterol in the brain
may have therapeutic benefit in AD (Di Paolo and Kim, 2011;
Sanchez-Mejia et al., 2008).
In this study, we find that blockingMAGL substantially reduces
neuroinflammation that underlies AD pathogenesis and attenu-
ates amyloidosis, likely through suppressing proinflammatory
eicosanoid production. Our results thus highlight MAGL inhibi-
tors as an attractive therapeutic strategy for treating AD.
EXPERIMENTAL PROCEDURES
Mice and Chemicals
Mgll/ mice (Chanda et al., 2010) were crossed with PS1/APP+ transgenic
mice (Samaroo et al., 2012) to create the four genotypes used in these studies:
Mgll+/+/PS1/APP, Mgll+/+/PS1/APP+, Mgll//PS1/APP, and Mgll//PS1/
APP+. All experiments were conducted in accordance with Pfizer’s IACUC
guidelines. The compounds JZL184 and rimonabant were synthesized in the
laboratory (Pfizer Inc.). AM 630 was purchased from Tocris Bioscience
(Minneapolis, MN)., 617–623, June 28, 2012 ª2012 The Authors 621
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Figure 4. Pharmacological Inactivation of MAGL Reduces Eicosa-
noids and Lowers Inflammatory Cytokine Levels
(A and B) Endocannabinoid and eicosanoid (A) and inflammatory cytokine (B)
levels in the brains of PS1/APP and PS1/APP+ mice treated, starting at
6months, with either vehicle, JZL184 (40mg/kg i.p.), or coadministration of the
CB1 and CB2 antagonists, rimonabant (RIM) (3 mg/kg), and AM 630 (3 mg/kg
i.p.), respectively, once per day over 16 days. Endocannabinoid and eicosa-
noid levels were determined by MRM-based targeted LC/MS analysis and raw
data are presented in Table S1. Inflammatory cytokineswere quantitated using
ELISA from soluble proteomes from hemi-brains. Data are means ± SEM,
n = 4–8mice/group. Significance is shown as *p < 0.05, **p < 0.01 using a linear
model ANOVAwith no correction for multiplicity because of small sample sizes
(A) and an ANOVA with Tukey-Kramer post-hoc test for (B).mRNA Expression of Proinflammatory Cytokines and Receptors
Brains from transgenic or pharmacologically treated animals were dissected
and rapidly frozen in liquid nitrogen. Total RNA was isolated from frozen
tissues and gene expression was assessed by quantitative RT-PCR.
Metabolomic Analysis
Metabolomic analysis was performed as previously described (Nomura et al.,
2011). Briefly, mice were sacrificed by cervical dislocation and brains were
removed rapidly (%30 s) and snap frozen in liquid nitrogen. Metabolites
were extracted in 3 ml of 1:1 ethyl acetate:hexane and 1 ml PBS. An aliquot
of the organic extract was injected onto a triple quadrupole-LC/MS/MS for
untargeted and targeted metabolite analysis. We combined data obtained
from both of these analytic procedures and have tabulated relative levels of
metabolites in Table S1.
Measurement of Proinflammatory Cytokine Levels
Cytokines were measured from soluble brain proteome (25 mg) using
the Mouse Inflammatory Cytokines Multi-Analyte ELISArray kit (QIAGEN,622 Cell Reports 1, 617–623, June 28, 2012 ª2012 The AuthorsValencia, CA) per a modified version of the manufacturer’s instructions.
More details are in Supplemental Information.
Immunohistochemistry and Plaque Quantitation
Four representative slides from each animal were incubated with anti-GFAP
(Millipore, USA) or anti-Iba1 (Wako, Japan) to determine the activation of astro-
cytes or microglia respectively. Sections were also stained with thioflavin S.
Multiple equivalent sections across each sample were imaged and thioflavin
S+ plaques counted using a computer algorithm developed at Pfizer.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
two figures, and one table and can be found with this article online at
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